drugset
drugset / Trial / NCT02678741

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

NCT02678741 ↗

Phase 1/2 Completed 26 enrolled Elios Therapeutics, LLC LumaBridge · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Assess the safety and tumor response of utilizing an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine given in combination with standard of care (SoC) checkpoint inhibitors (CPI) in patients with stage IV melanoma with measurable disease.

Timeline

Start
2016-02
Primary completion
2019-10-30
Completion
2019-11-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator TLPLDC Vaccine Vaccine 1e+06 cells —

Indications

metastatic melanoma